USE OF STANNIOCALCIN 2 IN THE TREATMENT OF TYPE II DIABETES AND COMPLICATIONS THEREOF

摘要

The present invention provides a definitive localization of human stanniocalcin 2 mRNA to the pancreas and further localizes stanniocalcin 2 protein synthesis to the pancreatic alpha cells. Also, the present invention demonstrates a correlation between an increase in plasma stanniocalcin 2 and plasma insulin which is lost in individuals suffering from type II diabetes mellitus. These data demonstrate that therapeutic and prophylactic amounts of a composition comprising human stanniocalcin 2 and biologically functional derivatives and fragments thereof are useful in the modulation of glucose homeostasis. In particular, methods for the use of human stanniocalcin 2 in the diagnosis and treatment of type II diabetes and chronic conditions associated therewith are provided.